Concert Pharmaceuticals - CNCE Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CNCE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CNCE, but not buy additional shares or sell existing shares.
View CNCE analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 12-month price objectives for Concert Pharmaceuticals' stock. Their CNCE share price forecasts range from $17.00 to $25.00. On average, they expect the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 150.9% from the stock's current price.
View analysts price targets for CNCE or view top-rated stocks among Wall Street analysts.

Concert Pharmaceuticals' stock was trading at $5.84 at the start of the year. Since then, CNCE shares have increased by 43.3% and is now trading at $8.37.
View the best growth stocks for 2023 here.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) issued its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.03. The biotechnology company had revenue of $0.54 million for the quarter, compared to analysts' expectations of $0.25 million. During the same quarter last year, the company posted ($0.60) earnings per share.

ETFs with the largest weight of Concert Pharmaceuticals (NASDAQ:CNCE) stock in their portfolio include iShares Biotechnology ETF (IBB) and ProShares Ultra Nasdaq Biotechnology (BIB).

1 employees have rated Concert Pharmaceuticals Chief Executive Officer Roger Tung on Glassdoor.com. Roger Tung has an approval rating of 100% among the company's employees. This puts Roger Tung in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Concert Pharmaceuticals investors own include Gilead Sciences (GILD), Eiger BioPharmaceuticals (EIGR), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Celldex Therapeutics (CLDX), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT) and Intel (INTC).

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

Concert Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Nantahala Capital Management LLC (3.61%), Millennium Management LLC (3.01%), Point72 Asset Management L.P. (2.80%), Bank of America Corp DE (2.73%), Ingalls & Snyder LLC (2.70%) and Tang Capital Management LLC (2.40%). Insiders that own company stock include Heek Christi Van, James V Cassella, Jeffrey A Munsie, Marc A Becker, Nancy Stuart, Peter Barton Hutt and Roger D Tung.
View institutional ownership trends.

Shares of CNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CNCE stock can currently be purchased for approximately $8.37.

Concert Pharmaceuticals (NASDAQ:CNCE) has a market capitalization of $401.26 million and generates $32.58 million in revenue each year. The biotechnology company earns $-80,050,000.00 in net income (profit) each year or ($3.21) on an earnings per share basis.

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The official website for the company is www.concertpharma.com. The biotechnology company can be reached via phone at (781) 860-0045, via email at ir@concertpharma.com, or via fax at 302-636-5454.